[1]IDF Diabetes Atlas 10th edition 2021. https://diabetesatlas.org/atlas/tenth-edition/.2023.12.07.

[2]中华医学会糖尿病学分会.中国2型糖尿病防治指南,2020, [J].中华糖尿病杂志, 2021, 13(4) : 315-409.

[3]Paul S, Ali A, Katare R. Molecular complexities underlying the vascular complications of diabetesmellitus-A comprehensive review. [J]. Diabetes Complications. 2020;34(8):107613. 

[4]Zhang Y, Hu G, Yuan Z, , et al. Glycosylated hemoglobin in relationship to cardiovascular outcomes and death in patients with type 2 diabetes: a systematic review and meta-analysis. [J]. PLoS One. 2012;7(8):e42551. 

[5]Wright RJ, Frier BM. Vascular disease and diabetes: is hypoglycaemia an aggravating factor?. [J].Diabetes Metab Res Rev. 2008;24(5):353-363.

[6]Zhao Y, Campbell CR, Fonseca V, et al. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes. [J]. Diabetes Care. 2012;35(5):1126-1132. 

[7]ORIGIN Trial Investigators, Mellbin LG, Rydén L, et al. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. [J]. Eur Heart J. 2013;34(40):3137-3144. 

[8]中华医学会内分泌学分会. 糖尿病患者血糖波动管理专家共识[J]. 中华内分泌代谢杂志,2017,33(8):633-636.

[9]毕宇芳. 2型糖尿病合并慢性肾脏病患者口服降糖药治疗中国专家共识（2019年更新版）解读[J].内科理论与实践,2019,14(06):333-336.

[10]Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. [J]. Cardiovasc Diabetol. 2011;10:19. 

[11]DeVries JH. Glucose variability: where it is important and how to measure it. Diabetes. 2013;62(5):1405-1408. doi:10.2337/db12-1610

[12]周健，贾伟平，马晓静， 等. 糖化血红蛋白控制理想的2型糖尿病患者血糖波动特征及其与微量白蛋白尿的关系. [J]. 中华医学杂志, 2008, 88 (42): 2977-81

[13]Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. [J]. Diabetes. 2003;52(11):2795-2804. 

[14]Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. [J]. Lancet. 2014;383(9922):1068-1083. 

[15]Lipska KJ, Yao X, Herrin J, et al. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. [J]. Diabetes Care. 2017;40(4):468-475. doi:10.2337/dc16-0985

[16]Drucker DJ. The biology of incretin hormones. [J]. Cell Metab. 2006;3(3):153-165. 

[17]Hinke SA, Hellemans K, Schuit FC. Plasticity of the beta cell insulin secretory competence: preparing the pancreatic beta cell for the next meal. [J]. J Physiol. 2004;558(Pt 2):369-380. 

[18]Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. [J]. Diabetes. 2000;49(11):1751-1760. 

[19]Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. [J]. Diabetes. 2004;53 Suppl 3:S48-S58. 

[20]Lau J, Bloch P, Schäffer L, et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. [J].  J Med Chem. 2015;58(18):7370-7380. 

[21]Kapitza C, Nosek L, Jensen L, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. [J]. J Clin Pharmacol. 2015;55(5):497-504. 

[22]Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. [J]. Eur J Intern Med. 2014;25(5):407-414. 

[23]Kapitza C, Dahl K, Jacobsen JB, et al. Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial. [J]. Diabetologia. 2017;60(8):1390-1399. 

[24]Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. [J]. Lancet Diabetes Endocrinol. 2017;5(4):251-260.

[25]Ahrén B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. [J]. Lancet Diabetes Endocrinol. 2017;5(5):341-354. 

[26]Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. [J]. Diabetes Care. 2018;41(2):258-266. 

[27]Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. [J]. Lancet Diabetes Endocrinol. 2017;5(5):355-366. 

[28]Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. [J]. J Clin Endocrinol Metab. 2018;103(6):2291-2301. 

[29]Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. [J]. Lancet Diabetes Endocrinol. 2018;6(4):275-286. 

[30]Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. [J]. Lancet Diabetes Endocrinol. 2019;7(11):834-844. 

[31]Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial  [J].Lancet Diabetes Endocrinol. 2019;7(5):356-367.

[32]Khoo CM, Deerochanawong C, Chan SP, et al. Use of sodium-glucose co-transporter-2 inhibitors in Asian patients with type 2 diabetes and kidney disease: An Asian perspective and expert recommendations. [J]. Diabetes Obes Metab. 2021;23(2):299-317. 

[33]Aroda VR, Capehorn MS, Chaykin L, et al. Impact of baseline characteristics and beta-cell function on the efficacy and safety of subcutaneous once-weekly semaglutide: A patient-level, pooled analysis of the SUSTAIN 1-5 trials. [J]. Diabetes Obes Metab. 2020;22(3):303-314. 

[34]Zierath JR. Major Advances and Discoveries in Diabetes - 2019 in Review. [J].Curr Diab Rep. 2019;19(11):118.